CORONA Remedies Presents Investor Presentation for Feb 2026
CORONA Remedies reported Q3 FY26 revenue of ₹342 Cr (up 15.0% YoY) and 9M FY26 revenue of ₹1,050 Cr (up 16.3% YoY). EBITDA for 9M FY26 was ₹231 Cr, and Adjusted PAT was ₹154 Cr. The company secured EAEU-GMP certification for its Bhayla facility, enabling entry into Eurasian markets. Chronic therapies formed 71.6% of 9M FY26 revenue.
The investor presentation provides an update on financial performance and strategic initiatives, which is important for investors but does not represent a singular, transformative event.
The announcement details positive financial performance, including strong revenue growth and improved margins, along with significant regulatory certifications that open new market opportunities.
CORONA Remedies Limited has released an investor presentation for February 2026, detailing its financial and operational performance for Q3 and 9M FY26.
The company reported healthy revenue growth of 15.0% in Q3 and 16.3% in 9M FY26 year-on-year, reaching ₹342 Cr and ₹1,050 Cr respectively. EBITDA stood at ₹83 Cr for Q3FY26, with a margin of 24.3%, and ₹231 Cr for 9MFY26 with a margin of 22.0%. Adjusted Profit After Tax (PAT) was ₹55.6 Cr for Q3FY26 and ₹154.1 Cr for 9MFY26, with margins of 16.2% and 14.7% respectively. The Bhayla facility received EAEU-GMP certification in January 2026, opening access to five key Eurasian markets.
Chronic therapies continue to be a strong contributor, accounting for 71.6% of total revenue in 9M FY26. The company maintained strong return ratios, with ROE at 31.1% and ROCE at 48.0% for 9MFY26 (annualised and excluding one-time statutory impact).
The presentation also highlighted the company's journey, manufacturing facilities, experienced management team, and ESG initiatives, including a solar power plant and ETP at the Bhayla facility. Strategic growth plans include increasing market share in the domestic market, expanding into new therapeutic areas, product portfolio management, strategic acquisitions, and expanding sales in select overseas markets.
The company's growth has outpaced the Indian Pharmaceutical Market (IPM), with revenue CAGR of 16.8% compared to IPM's 9.2% over MAT Jun-22 to MAT Jun-25.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.